ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook For full year 2024, the Company expects total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS to be at or above the guidance ranges provided on November 8, 2024Rare Disease Segment performed in line with expectations, with Purified Cortrophin Gel net revenues of $197.8 million to $198.4 million for the full year 2024 and ILUVIEN and YUTIQ net revenues of $30.4 million to $31.0 million for the post-acquisition period from September 16, 2024 to December 31,...
CECO Environmental Announces Closing of Acquisition of Profire Energy Advances CECO’s Position as the Leading Environmental Solutions Provider in Industrial Markets ADDISON, Texas, Jan. 09, 2025 (GLOBE NEWSWIRE) -- CECO Environmental Corp. (Nasdaq: CECO) (“CECO”), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment, and industrial equipment, today announced the closing of its acquisition of Profire Energy, Inc., as of January 3, 2025, (formerly NASDAQ: PFIE) (“Profire”), a technology company and industry-leading provider of ...
CECO Environmental to Present at the 27th Annual Needham Growth Conference on January 17 ADDISON, Texas, Jan. 07, 2025 (GLOBE NEWSWIRE) -- CECO Environmental Corp. (Nasdaq: CECO), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment and industrial equipment, today announces that CECO Management will present at the following investor conference in January: January 17, 2025 – The 27th Annual Needham Growth Conference Virtual – 9:30 am ET presentation and conducting meetings throughout the day. The webcast presentation will be av...
CECO Environmental Announces Expiration of Tender Offer Period for Outstanding Shares of Profire Energy ADDISON, Texas, Jan. 02, 2025 (GLOBE NEWSWIRE) -- CECO Environmental Corp. (Nasdaq: CECO) (together with its consolidated subsidiaries and affiliates, “CECO”), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment and industrial equipment, today announced the successful completion of the previously announced tender offer (the “Offer”) to acquire all of the issued and outstanding shares (the “Shares”) of Profire Energy, Inc. (Na...
ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company has launched Prucalopride Tablets. ANI’s Prucalopride Tablets is the generic version of the reference listed drug (RLD) Motegrity®. "We are delighted to build momentum early in 2025 with the approval of the fir...
ANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference PRINCETON, N.J., Dec. 30, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer; Stephen Carey, Chief Financial Officer; and Dr. Mary Pao, Chief Medical Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 2:15pm PST/5:15pm EST, in San Francisco. The live and archived webcast will be accessible from the Company’s website at , under the Inves...
A director at Agree Realty Corp bought 30,275 shares at 70.244USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
A director at ANI Pharmaceuticals Inc sold 7,500 shares at 55.790USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
CECO Environmental Announces Expiration of HSR Waiting Period ADDISON, Texas, Dec. 05, 2024 (GLOBE NEWSWIRE) -- CECO Environmental Corp. (Nasdaq: CECO) (together with its consolidated subsidiaries and affiliates, “CECO”), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment and industrial equipment, announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), applicable to CECO’s tender offer for Profire Energy, Inc. (Nasdaq: PFIE) (“PFIE”) expired at 11:59 p.m., Eas...
CECO Environmental Announces Commencement of the Tender Offer for All Outstanding Shares of Profire Energy ADDISON, Texas, Dec. 03, 2024 (GLOBE NEWSWIRE) -- CECO Environmental Corp. (Nasdaq: CECO) (together with its consolidated subsidiaries and affiliates, “CECO”), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment and industrial equipment, announced today that its affiliate, Combustion Merger Sub, Inc. (“Purchaser”), commenced the previously announced cash tender offer for all of the issued and outstanding shares of common s...
ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference PRINCETON, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024 at 3pm EST in NYC. The live and archived webcast will be accessible from the Company’s website at , under the Investors section under Events and Presentations. The...
ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance Generated record quarterly net revenues of $148.3 million, representing year-over-year growth of 12.5%, and record Purified Cortrophin® Gel net revenues of $52.6 million, an increase of 76.8% year-over-yearNet loss of $(24.2) million and adjusted non-GAAP EBITDA of $35.1 millionDiluted GAAP loss per share of $(1.27) and adjusted non-GAAP diluted earnings per share of $1.34Completed the acquisition of Alimera Sciences, Inc. on September 16, 2024, adding two commercial assets ILUVIEN® and YUTIQ® w...
CECO Environmental Announces Upcoming Investor Conferences DALLAS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- CECO Environmental Corp. (Nasdaq: CECO), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment and industrial equipment, today announces that CECO Management will present at the following investor conferences: • November 12, 2024 – The Baird’s Global Industrials Conference Chicago – 10:15 am CT presentation and conducting meetings throughout the day. • November 21, 2024 – The 16th Annual Southwest IDEAS Conference Dallas - 2:4...
ANI Pharmaceuticals to Present at Guggenheim's Inaugural Healthcare Innovation Conference and Jefferies London Healthcare Conference in November PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at at two upcoming investor conferences as follows: • The Guggenheim Inaugural Healthcare Innovation Conference Wednesday, November 13, 2024, at 10:00am ET • The Jefferies London Healthcare C...
ANI Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 8, 2024, at 8:00 a.m. ET PRINCETON, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2024 financial results on Friday, November 8, 2024, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as fo...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.